1. Introduction {#sec1-cancers-11-01493}
===============

Survival of patients belonging to the unfavorable risk groups of myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemias (CMML) and acute myeloid leukemias (AML) is poor after standard antileukemic therapy \[[@B1-cancers-11-01493],[@B2-cancers-11-01493],[@B3-cancers-11-01493],[@B4-cancers-11-01493],[@B5-cancers-11-01493]\]. Resistance to classical "7 + 3 chemotherapy" (cytarabine, daunorubicin) is common, and a substantial proportion of these patients is not eligible for allogeneic bone marrow transplantation. DNA methyltransferase inhibitors (DNMTi) (e.g., decitabine, azacytidine) may facilitate temporary remissions \[[@B6-cancers-11-01493],[@B7-cancers-11-01493],[@B8-cancers-11-01493],[@B9-cancers-11-01493],[@B10-cancers-11-01493]\]; however, after failure to DNMTi, the median overall survival decreases to below six months \[[@B11-cancers-11-01493],[@B12-cancers-11-01493],[@B13-cancers-11-01493],[@B14-cancers-11-01493]\].

Recent advances in the understanding of the biology of MDS/CMML and AML led to the development of novel targeted and untargeted agents (e.g., IDH inhibitors, FLT3 inhibitors, splicing modulators, novel DNMTi, anti-CD33 antibodies) \[[@B15-cancers-11-01493],[@B16-cancers-11-01493],[@B17-cancers-11-01493],[@B18-cancers-11-01493],[@B19-cancers-11-01493],[@B20-cancers-11-01493]\]. In this context, inhibitors of poly(ADP-ribose) polymerase (PARP) 1/2 and apurinic/apyrimidinic endonuclease (APE) 1 may represent innovative DNA repair inhibitors that target MDS/CMML and AML cells by inhibition of single-strand break repair (SSB-R) and base excision repair (BER), respectively.

Talazoparib is a potent inhibitor of PARP1, which is involved in SSB-R and BER \[[@B21-cancers-11-01493]\]. PARP1 senses and binds to single-strand breaks (SSBs) and synthesizes branched chains of poly(ADP-ribose) of up to several hundred units in length on itself and target proteins \[[@B22-cancers-11-01493],[@B23-cancers-11-01493],[@B24-cancers-11-01493]\]. Talazoparib leads to the accumulation of SSBs, which may convert into DNA double-strand breaks (DSBs) eventually leading to cell death in DSB repair deficient cells \[[@B25-cancers-11-01493],[@B26-cancers-11-01493]\]. In addition, talazoparib traps PARP1 at sites of damaged DNA and generates cytotoxic PARP1-DNA complexes, which may account for the main cytotoxic efficacy \[[@B27-cancers-11-01493]\]. Recently, it has been demonstrated that low doses of DNMTi increase the trapping of PARP1 on DNA, which may enhance the killing of leukemic cells \[[@B28-cancers-11-01493]\].

The APE1 inhibitor III inhibits APE1 \[[@B29-cancers-11-01493]\], which is a key protein in BER \[[@B30-cancers-11-01493]\]. After resection of the damaged base by glycosylases, APE1 cleaves the phosphodiester bound and creates a nick 5´ to the apurinic/apyrimidinic (AP) site. The AP site is then processed either by the short patch or the long patch BER pathway \[[@B31-cancers-11-01493],[@B32-cancers-11-01493]\]. Inhibition of APE1 causes accumulation of AP sites, which block regular DNA synthesis \[[@B33-cancers-11-01493]\]. As a result, stalled replication forks may collapse and convert into DSB \[[@B34-cancers-11-01493]\], which then leads to death in DSB repair deficient leukemic cells \[[@B35-cancers-11-01493]\].

Finally, 5-aza-2´-deoxycytidine (decitabine) is a potent DNMTi, which is used for the treatment of MDS/CMML \[[@B6-cancers-11-01493],[@B7-cancers-11-01493],[@B8-cancers-11-01493]\] and AML \[[@B7-cancers-11-01493],[@B10-cancers-11-01493]\]. Although the exact mechanism of action is not yet fully understood, it has been shown that decitabine modifies the epigenetic signature in MDS/CMML and AML cells and induces cell death by activation of tumor suppressor genes and silencing of oncogenes \[[@B36-cancers-11-01493],[@B37-cancers-11-01493]\]. In addition, decitabine is misincorporated as a cytosine analogue during DNA replication and binds covalently DNMT1 to form cytotoxic DNMT1-DNA complexes \[[@B38-cancers-11-01493]\].

In this study, we analyzed the antileukemic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells with defects in DSB repair. The cytotoxic efficacy of talazoparib and APE1 inhibitor III were tested alone, combined with decitabine, and combined with each other in primary CD34+ MDS/CMML cells and in primary CD34+ or CD34− AML cells in comparison to healthy CD34+ donor cells. We further analyzed the correlation of distinct parameters and biomarkers including cell proliferation, *PARP1*/*APE1* mRNA expression, *γ*H2AX foci levels, chromosomal aberrations, and gene mutations with cell survival.

2. Results {#sec2-cancers-11-01493}
==========

2.1. Cytotoxic Efficacy of Talazoparib and APE1 Inhibitor III in MDS/CMML and AML Cells {#sec2dot1-cancers-11-01493}
---------------------------------------------------------------------------------------

The cytotoxic efficacy of talazoparib and APE1 inhibitor III was analyzed after 3 d of initial expansion followed by 3 d of treatment in CD34+ MDS/CMML cells (*n* = 8; 4 MDS and 4 CMML samples) and in CD34+ or CD34− AML cells (*n* = 18) in comparison to healthy CD34+ donor cells (*n* = 8) ([Table 1](#cancers-11-01493-t001){ref-type="table"}, [Figure 1](#cancers-11-01493-f001){ref-type="fig"}). The comparison of IC~50~ values showed significantly increased (*p* = 0.016) cytotoxic efficacy of talazoparib in 2 MDS/CMML (MDS\#2, CMML\#2) and 3 AML cell samples (AML\#1, AML\#2, AML\#3) (7 nM ± 2 (mean IC~50~ ± standard error of mean)) as compared to the 8 healthy donor cell samples (16 nM ± 2) ([Figure 1](#cancers-11-01493-f001){ref-type="fig"}A). The 'responder rate' of MDS/CMML/AML samples towards talazoparib was about 19%. Furthermore, the cytotoxic efficacy of APE1 inhibitor III was substantially increased (*p* = 0.059) in 1 MDS (MDS\#2) and 5 AML cell samples (AML\#1, AML\#2, AML\#3, AML\#6, AML\#12) (603 nM ± 71) as compared to the cytotoxic efficacy in 8 healthy donor cell samples (1041 nM ± 149) ([Figure 1](#cancers-11-01493-f001){ref-type="fig"}B). The 'responder rate' of MDS/CMML/AML samples towards APE1 inhibitor III was about 25%. Interestingly, 1 MDS (MDS\#2) and 3 AML samples (AML\#1-3) were 'responders' towards both talazoparib and APE1 inhibitor III.

The cell proliferation rate of MDS/CMML and AML cells might correlate with the cytotoxic efficacy of talazoparib and APE1 inhibitor III, respectively. Therefore, growth curves of untreated MDS/CMML and AML cells were correlated with the corresponding surviving fractions of talazoparib and APE1 inhibitor III treated MDS/CMML and AML cells ([Figure 1](#cancers-11-01493-f001){ref-type="fig"}C,D). However, no consistent correlation between cell proliferation and cytotoxic efficacy of talazoparib and APE1 inhibitor III was evident in MDS/CMML and AML cells. These findings suggest that the antileukemic efficacy of talazoparib and APE1 inhibitor III is not strictly dependent on the in vitro proliferation rate of leukemic blasts.

2.2. Cytotoxic Efficacy of Decitabine ± Talazoparib, Decitabine ± APE1 Inhibitor III, and Talazoparib ± APE1 Inhibitor III in MDS/CMML and AML Cells {#sec2dot2-cancers-11-01493}
----------------------------------------------------------------------------------------------------------------------------------------------------

The cytotoxic efficacies of (I) decitabine ± talazoparib, (II) decitabine ± APE1 inhibitor III, and (III) talazoparib ± APE1 inhibitor III were analyzed in CD34+ MDS/CMML cells and in CD34+ or CD34− AML cells ([Table 1](#cancers-11-01493-t001){ref-type="table"}, [Figure 2](#cancers-11-01493-f002){ref-type="fig"}). Subtoxic doses of talazoparib (2--2.5 nM) added to decitabine substantially decreased the surviving fraction in 4 MDS (MDS\#1-4), 4 CMML (CMML\#1--4), and 10 AML (AML\#1, AML\#3--6, AML\#10, AML\#11, AML\#15--17) cell samples ([Table 1](#cancers-11-01493-t001){ref-type="table"}, [Figure 2](#cancers-11-01493-f002){ref-type="fig"}A,B). Further, subtoxic doses of APE1 inhibitor III (50 nM) added to decitabine substantially decreased the surviving fraction in 1 MDS (MDS\#3), 4 CMML (CMML\#1--4), and 10 AML (AML\#1, AML\#3--5, AML\#7, AML\#8, AML\#10, AML\#11, AML\#16, AML\#17) cell samples ([Table 1](#cancers-11-01493-t001){ref-type="table"}, [Figure 2](#cancers-11-01493-f002){ref-type="fig"}C,D). Finally, low subtoxic doses of APE1 inhibitor III (50 nM) added to talazoparib substantially decreased the surviving fraction in 2 MDS (MDS\#2, MDS\#3), 3 CMML (CMML\#2--4), and 7 AML (AML\#1, AML\#3, AML\#5, AML\#7, AML\#10, AML\#11, AML\#17) cell samples ([Table 1](#cancers-11-01493-t001){ref-type="table"}, [Figure 2](#cancers-11-01493-f002){ref-type="fig"}E,F).

2.3. Analysis of PARP1 and APE1 mRNA Expression in MDS/CMML and AML Cells in Correlation to Cytotoxic Efficacy of Talazoparib and APE1 Inhibitor III {#sec2dot3-cancers-11-01493}
----------------------------------------------------------------------------------------------------------------------------------------------------

*PARP1* and *APE1* mRNA expression might correlate with the cytotoxic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells and explain why some of the patients did not respond to the drugs. Therefore, *PARP1* and *APE1* mRNA expression levels were analyzed in MDS/CMML and AML cell samples. However, the *PARP1* and *APE1* mRNA expression levels did not differ significantly between 'responders' and 'non-responders' ([Figure 3](#cancers-11-01493-f003){ref-type="fig"}A,B).

2.4. Analysis of γH2AX Foci in MDS/CMML and AML Cells in Correlation to Cytotoxic Efficacy of Talazoparib and APE1 Inhibitor III {#sec2dot4-cancers-11-01493}
--------------------------------------------------------------------------------------------------------------------------------

Since both drugs act on the DNA damage response, *γ*H2AX foci (as a readout for DNA damage) were analyzed for their potential correlation with the cytotoxic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells. Therefore, *γ*H2AX foci levels were quantified in MDS/CMML and AML cell samples. However, the number of *γ*H2AX foci did not significantly differ between 'responders' and 'non-responders' ([Figure 3](#cancers-11-01493-f003){ref-type="fig"}C,D).

2.5. Analysis of Chromosomal Aberrations and Gene Mutations in Correlation to Cytotoxic Efficacy of Talazoparib and APE1 Inhibitor III {#sec2dot5-cancers-11-01493}
--------------------------------------------------------------------------------------------------------------------------------------

Distinct chromosomal aberrations and gene mutations might correlate with the cytotoxic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells. Therefore, a comprehensive analysis of chromosomal aberrations and gene mutations was performed in MDS/CMML and AML cell samples ([Table 2](#cancers-11-01493-t002){ref-type="table"} and [Table 3](#cancers-11-01493-t003){ref-type="table"}). Cytogenetic analysis revealed no specific chromosomal aberrations that predicted sensitivity towards talazoparib or APE1 inhibitor III. However, 100% of the talazoparib 'responders' (MDS\#2, CMML\#2, AML\#1--3) and 83% of the APE1 inhibitor III 'responders' (MDS\#2, AML\#1--3, AML\#6) displayed a normal karyotype. In addition, gene mutation analysis revealed that 50% of *KMT2A-PTD* mutated AML samples (AML\#2, AML\#3), 50% of *NRAS* mutated AML samples (AML\#2, AML\#3), and 67% of *U2AF1* mutated MDS/AML samples (MDS\#2, AML\#3) were sensitive towards talazoparib and APE1 inhibitor III, respectively. On the other hand, the AML sample (AML\#12) most insensitive towards talazoparib (IC~50~ 505 nM) was *TP53-*mutated and harbored a complex karyotype. Further, the AML sample (AML\#9) most insensitive towards APE1 inhibitor III (IC~50~ 5781 nM) was *DNMT3A-*, *FLT3-TKD-*, *IDH1-*, *NPM1-*, *NRAS-*mutated and harbored a normal karyotype.

3. Discussion {#sec3-cancers-11-01493}
=============

In the present study, the cytotoxic efficacy of talazoparib and APE1 inhibitor III was investigated using several distinct approaches in CD34+ MDS/CMML cells and in CD34+ or CD34− AML cells in comparison to healthy CD34+ donor cells. In addition, potential predictive markers were analyzed and correlated with the cytotoxic efficacy of talazoparib and APE1 inhibitor III.

Talazoparib demonstrated critical antileukemic efficacy as a single-agent and in combination with decitabine in several MDS/CMML and AML cell samples, which might be mediated by the formation of cytotoxic PARP1-DNA complexes \[[@B27-cancers-11-01493]\], DNMT1-DNA complexes \[[@B38-cancers-11-01493]\], and PARP1-DNMT1-DNA complexes \[[@B28-cancers-11-01493]\], respectively. Notably, our data suggest that decitabine combined with low doses of talazoparib might kill MDS/CMML and AML cells more efficiently than decitabine alone, as demonstrated by an increased antileukemic efficacy for the combination in about 86% of MDS/CMML/AML cell samples. Our observations confirm and extend results of previous experimental studies reporting on the antileukemic efficacy of olaparib \[[@B39-cancers-11-01493],[@B40-cancers-11-01493],[@B41-cancers-11-01493]\] and talazoparib \[[@B28-cancers-11-01493]\] and the synergistic efficacy between talazoparib and DNMTi in AML cell lines and primary AML cells \[[@B28-cancers-11-01493]\]. Currently, the antileukemic efficacy of talazoparib alone and combined with decitabine has been tested in several clinical trials \[[@B42-cancers-11-01493],[@B43-cancers-11-01493],[@B44-cancers-11-01493]\].

Furthermore, APE1 inhibitor III demonstrated antileukemic efficacy in several MDS/CMML and AML cell samples. The 'responder' rate of 25% in MDS/CMML/AML cell samples treated with APE1 inhibitor III was similar to the 'responder' rate of 19% in MDS/CMML/AML cell samples treated with talazoparib. However, APE1 inhibitor III exhibited about 30-fold less potent IC~50~ values as compared to talazoparib. Our observations are in accordance with the more advanced development of PARP inhibitors (e.g., talazoparib) as compared to APE1 inhibitors (e.g., APE1 inhibitor III). Despite the inferior potency of APE1 inhibitor III, subtoxic doses increased the antileukemic efficacy of decitabine and talazoparib in about 78% and 68% of MDS/CMML/AML cell samples, respectively. As BER is presumed to be involved in the repair of decitabine-induced DNA lesions \[[@B45-cancers-11-01493]\], we hypothesize that APE1 inhibitor III might interact synergistically with decitabine by interruption of BER. Further, APE1 inhibitor III might interact synergistically with talazoparib by inducing suicidal cross-linking of PARP1 to AP sites \[[@B46-cancers-11-01493]\].

Markers predicting the cytotoxic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells are, so far, largely unknown. Therefore, several markers including cell proliferation, PARP1/APE1 mRNA expression, *γ*H2AX foci levels, chromosomal aberrations, and gene mutations were analyzed and correlated with cell survival of MDS/CMML and AML cells after treatment with talazoparib and APE1 inhibitor III, respectively. Cell proliferation, *PARP1*/*APE1* mRNA expression, and *γ*H2AX foci levels demonstrated no consistent correlation with the cytotoxic efficacy of talazoparib and APE1 inhibitor III in MDS/CMML and AML cells. Furthermore, no specific chromosomal aberrations with a predictive impact were detected. However, 100% of the talazoparib 'responders' and 83% of the APE1 inhibitor III 'responders' displayed a normal karyotype. Finally, gene mutation analysis suggested that *KMT2A-PTD, NRAS,* and *U2AF1* mutations might be associated with a sensitivity rate of 50% or more towards talazoparib and APE1 inhibitor III, respectively.

Resistance to PARP inhibitors is a major clinical problem. Several categories of PARP inhibitor resistance mechanisms have been described to date and can be assigned to (I) increased drug efflux (e.g., upregulation of ABC transporters), (II) decreased trapping of PARP1 on DNA (e.g., trapping-diminishing PARP1 mutations), (III) restoration of homologous recombination (e.g., reactivation of *BRCA1/2*, loss of 53BP1, loss of Shieldin factors), and (IV) stabilization of stalled forks (e.g., loss of PTIP or EZH2) (reviewed in \[[@B47-cancers-11-01493]\]). Further work is needed to clarify the role of these resistance mechanisms in MDS/CMML and AML. Possible mechanisms of resistance towards APE1 inhibitor III might include the expression of translesion polymerases (Pol) capable of bypassing AP sites or the upregulation of DSB repair genes.

4. Materials and Methods {#sec4-cancers-11-01493}
========================

4.1. Bone Marrow Samples {#sec4dot1-cancers-11-01493}
------------------------

This study was approved by the Ethics Committee II of the Medical Faculty of Mannheim at Heidelberg University (2018-566N-MA). Written, informed consent was obtained from all participants. Heparinized bone marrow (BM) samples were collected from 8 healthy donors (3 males, 5 females, mean age: 30 years), 8 MDS/CMML patients (4 MDS and 4 CMML; 5 males, 3 females, mean age: 70 years), and 18 AML patients (12 males, 6 females, mean age: 67 years) prior to antileukemic therapy ([Table 1](#cancers-11-01493-t001){ref-type="table"}).

Mononuclear cells were separated from BM samples by Ficoll density gradient centrifugation. CD34+ cells were enriched using CD34 microbeads and cell separation columns (CD34 MicroBead Kit, Miltenyi Biotec, Bergisch Gladbach, Germany). Healthy CD34+ donor cells, CD34+ MDS/CMML cells, and CD34+ or CD34− AML cells were grown in a humidified 5% CO~2~ atmosphere at 37 °C in StemSpan medium (Stemcell Technologies Germany GmbH, Köln, Germany) supplemented with StemSpan myeloid expansion supplement (SCF, TPO, G-CSF, GM-CSF) (Stemcell Technologies Germany GmbH) and 1% penicillin/streptomycin.

4.2. Cytology, Flow Cytometry, Cytogenetics, and Gene Mutation Analysis {#sec4dot2-cancers-11-01493}
-----------------------------------------------------------------------

MDS/CMML and AML BM samples were diagnosed according to standard procedures using cytomorphology (May-Grünwald/Giemsa stained BM smears), flow cytometry, G-banding cytogenetics, fluorescence in situ hybridization (FISH), and molecular mutation analysis \[[@B48-cancers-11-01493],[@B49-cancers-11-01493],[@B50-cancers-11-01493]\].

4.3. Cell Proliferation {#sec4dot3-cancers-11-01493}
-----------------------

Cell proliferation of untreated MDS/CMML and AML cells was determined by trypan blue exclusion assay at days 1, 2, and 3 \[[@B51-cancers-11-01493]\].

4.4. Immunofluorescence Staining of γH2AX {#sec4dot4-cancers-11-01493}
-----------------------------------------

Immunofluorescence staining of *γ*H2AX was performed in untreated healthy donor cells, MDS/CMML cells, and AML cells using a mouse monoclonal anti-*γ*H2AX antibody (clone JBW301; Merck Millipore, Darmstadt, Germany) and an Alexa Fluor 488-conjugated goat anti-mouse secondary antibody (Thermo Fisher Scientific, Waltham, MA, USA) as previously described \[[@B52-cancers-11-01493],[@B53-cancers-11-01493]\].

4.5. PARP1 and APE1 mRNA Expression {#sec4dot5-cancers-11-01493}
-----------------------------------

The mRNA expressions of *PARP1* and *APE1* were analyzed in healthy donor cells, MDS/CMML cells, and AML cells. For quantitative real-time PCR (qRT-PCR), the QuantiFast SYBR Green PCR Kit (Qiagen, Hilden, Germany) with commercial bioinformatically validated primer sets for *PARP1* (Hs_PARP1_1\_SG QuantiTect Primer Assay, NM_001618) (Qiagen) and *APE1* (Hs_APEX1_1\_SG QuantiTect Primer Assay, ENST00000216714) (Qiagen) was used according to manufacturer instructions. Normalization validation was performed with a primer set for the reference gene *GUSB* (Hs_GUSB_1\_SG QuantiTect Primer Assay, ENST00000304895) (Qiagen). Samples were analyzed in triplicate using the LightCycler 480 II system (Roche, Mannheim, Germany) equipped with 96-well plates with a total well volume of 25 µL containing primer mix (2.5 µL), SYBR Green Master Mix (12.5 µL), 20 ng template cDNA (2 µL), and PCR-grade water (8 µL). qRT-PCR was performed at thermal cycling conditions of 95 °C for 5 min, 95 °C for 10 s, and 60 °C for 30 s (×40 cycles).

4.6. Drug Stock Solutions {#sec4dot6-cancers-11-01493}
-------------------------

Stock solutions of 50 mM talazoparib III (Selleck Chemicals, Houston, TX, USA), 5 mM APE1 inhibitor III (Selleck Chemicals), and 50 mM decitabine (Merck, Darmstadt, Germany) were prepared by dissolving the agents in dimethylsulfoxide (DMSO) (Merck).

4.7. Cell Survival Assay {#sec4dot7-cancers-11-01493}
------------------------

The CellTiter-Glo luminescent cell viability assay (Promega, Southampton, UK) was used for the assessment of cell survival of healthy donor cells, MDS/CMML cells, and AML cells according to the manufacturer's instructions. Cryopreserved CD34+ MDS/CMML cells and CD34+ or CD34− AML cells were thawed and expanded in culture for 3 d followed by 3 d of daily drug exposure. The IC~50~ designated the drug concentration capable of killing 50% of the cells and was calculated with GraphPad Prism 5 software (GraphPad Software, La Jolla, US) by linear regression. MDS/CMML and AML patient samples were classified as 'responders' or 'non-responders' using a cutoff value of mean IC~50~ of healthy controls minus standard error of mean. Experiments were performed once owing to the limited availability of healthy CD34+ donor cells, CD34+ MDS/CMML cells, and CD34+ or CD34− AML cells. DMSO-treated cells were used as control.

4.8. Statistical Analysis {#sec4dot8-cancers-11-01493}
-------------------------

All statistical calculations were done with SAS software, release 9.4 (SAS Institute Inc., Cary, NC, USA). For quantitative variables, mean values and standard errors were calculated. Categorical factors are presented with absolute and relative frequencies. In order to compare more than two groups, Kruskal--Wallis tests were performed. For pairwise comparisons, Wilcoxon two-sample tests were used. Test results with *p* values \< 0.05 were considered as statistically significant.

For analysis of *PARP1* and *APE1* expressions, relative quantification was used according the ΔΔCT method. Normalization of target genes was performed using the arithmetic mean Ct of the nonregulated housekeeping gene *GUSB* from 6 healthy donor samples.

5. Conclusions {#sec5-cancers-11-01493}
==============

Our study performed on primary MDS/CMML and AML patient cells provides important preclinical data for a potential clinical use of talazoparib and APE1 inhibitor III alone and in combination with decitabine. In a next step, the in vivo antileukemic activities of talazoparib and APE1 inhibitor III need to be evaluated in clinical studies. Currently, talazoparib is tested as a single agent in advanced hematologic neoplasias (NCT01399840) \[[@B42-cancers-11-01493]\] and in cohesin-mutated AML and MDS with excess blasts (NCT03974217) \[[@B43-cancers-11-01493]\]. Further, decitabine and talazoparib are tested in patients with untreated and relapsed/refractory AML (NCT02878785) \[[@B44-cancers-11-01493]\]. APE1 inhibitor III may enter similar trials in MDS/CMML/AML in the future.
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![Cytotoxic efficacy of talazoparib and APE1 inhibitor III in healthy CD34+ donor cells, in CD34+ myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) cells, and in CD34+ or CD34− acute myeloid leukemia (AML) cells after initial expansion for 3 days followed by 3 days of treatment. (**A**) The mean IC~50~ of talazoparib was significantly lower (\* *p* = 0.016) in 1 MDS (MDS\#2), 1 CMML (CMML\#2), and 3 AML cell samples (AML\#1, AML\#2, AML\#3) as compared to 8 healthy donor cell samples. (**B**) The mean IC~50~ of APE1 inhibitor III was substantially lower (*p* = 0.059) in 1 MDS (MDS\#2) and 5 AML cell samples (AML\#1, AML\#2, AML\#3, AML\#6, AML\#12) as compared to 8 healthy donor cell samples. (**C**) Exemplary growth curves (left panel) and corresponding surviving fractions of 3 'responders' after initial expansion for 3 days followed by 3 days of treatment with talazoparib (mid panel) and APE1 inhibitor III (right panel). (**D**) Exemplary growth curves (left panel) and corresponding surviving fractions of 3 'non-responders' after initial expansion for 3 days followed by 3 days of treatment with talazoparib (mid panel) and APE1 inhibitor III (right panel). Error bars represent mean ± standard error of mean.](cancers-11-01493-g001){#cancers-11-01493-f001}

![Surviving fractions of CD34+ or CD34− acute myeloid leukemia (AML) cells after initial expansion for 3 days followed by 3 days of treatment with (I) decitabine ± talazoparib, (II) decitabine ± APE1 inhibitor III, and (III) talazoparib ± APE1 inhibitor III. (**A**,**B**) Exemplary surviving fractions of AML cells treated with decitabine ± talazoparib. (**C**,**D**) Exemplary surviving fractions of AML cells treated with decitabine ± APE1 inhibitor III. (**E**,**F**) Exemplary surviving fractions of AML cells treated with talazoparib ± APE1 inhibitor III.](cancers-11-01493-g002){#cancers-11-01493-f002}

![Cytotoxic efficacy of talazoparib and APE1 inhibitor III in CD34+ myelodysplastic syndrome (MDS)/chronic myelomonocytic leukemia (CMML) cells and in CD34+ or CD34− acute myeloid leukemia (AML) cells in relation to *PARP1*/*APE1* mRNA expression and *γ*H2AX foci levels. (**A**,**B**) *PARP1* and *APE1* mRNA expression levels in 'responders' and 'non-responders'. (**C**,**D**) Levels of γH2AX foci in 'responders' and 'non-responders'. Error bars represent mean ± standard error of mean.](cancers-11-01493-g003){#cancers-11-01493-f003}

cancers-11-01493-t001_Table 1

###### 

Characterization of myelodysplastic syndrome/chronic myelomonocytic leukemia and acute myeloid leukemia bone marrow samples. APE1i: APE1 inhibitor III; CMML-0/1/2: chronic myeloid leukemia-0/1/2; Dec: decitabine; FISH: fluorescence in situ hybridization; IC~50~: half maximal inhibitory concentration; MDS-EB-1: myelodysplastic syndrome with excess blasts; MDS-MLD: myelodysplastic syndrome with multilineage dysplasia; sAML: secondary acute myeloid leukemia; Tal: talazoparib.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \#           Age/Sex   Disease         Karyotype/FISH                                                                      Mutations                                                        IC~50~ \[nM\]                             
  ------------ --------- --------------- ----------------------------------------------------------------------------------- ---------------------------------------------------------------- --------------- ------ ----- ----- ------ -----
  HEALTHY\#1   25/♂      Healthy         46,XY\[20\]                                                                         \-                                                               20              1359   254   58    206    19

  HEALTHY\#2   23/♀      Healthy         46,XX\[20\]                                                                         \-                                                               28              392    23    \-    \-     \-

  HEALTHY\#3   77/♀      Healthy         46,XX\[20\]                                                                         \-                                                               12              1195   156   52    128    10

  HEALTHY\#4   26/♂      Healthy         46,XY\[20\]                                                                         \-                                                               10              882    99    24    55     7

  HEALTHY\#5   21/♂      Healthy         46,XY\[20\]                                                                         \-                                                               14              724    113   14    102    8

  HEALTHY\#6   22/♀      Healthy         46,XX\[20\]                                                                         \-                                                               10              1697   111   26    111    10

  HEALTHY\#7   21/♀      Healthy         46,XX\[20\]                                                                         \-                                                               14              1305   147   35    123    12

  HEALTHY\#8   25/♀      Healthy         46,XX\[20\]                                                                         \-                                                               17              775    186   23    166    11

  MDS\#1       59/♂      MDS-EB-1        46,XY,-7,der(9)t(9;20)(p21;q13),\                                                   CBL, DNMT3A (VAR),\                                              20              1357   160   48    137    19
                                         der(20)t(9;20)(p21;q11),+der(20)\                                                   EZH2 (VAR), FLT3-ITD                                                                                       
                                         t(9;20)(p21;q11)\[17\]/46,XY\[3\]                                                                                                                                                              

  MDS\#2       73/♀      MDS-MLD         46,XX\[20\]                                                                         ASXL1, GATA2, RUNX1, U2AF1                                       6               509    9     3     8      5

  MDS\#3       68/ ♂     MDS-MLD         45,X,-Y\[8\]/45,X,-Y,del(1)(p34p36)\[12\]                                           ASXL1, U2AF1                                                     26              1281   107   24    60     21

  MDS\#4       57♀       MDS-EB-1        46,XX\[20\]                                                                         ASXL1                                                            31              2921   185   89    181    36

  CMML\#1      77/♂      CMML-1          46,XY,t(2;2)(p23;q32)\[10\]/47,XY, t(2;2)(p23;q32),+8\[2\]/46,XY\[9\]               ASXL1, CEBPA, IDH1, RUNX1, SRSF2                                 28              1095   42    25    32     28

  CMML\#2      73/♀      CMML-2          46,XX\[20\]                                                                         ASXL1, CEBPA, EZH2 (VAR), TET2                                   13              1286   210   62    159    11

  CMML\#3      84/♂      CMML-0          46,XY\[20\]                                                                         DNMT3A, RUNX1, SRSF2, TET2                                       175             1008   121   42    67     47

  CMML\#4      65/♂      CMML-2          46,XY\[20\]                                                                         ASXL1, IDH2, NRAS, PTPN11, ZRSR2                                 47              1954   153   48    122    35

  AML\#1       79/♂      sAML            46,XY\[29\]                                                                         ASXL1, FLT3-ITD,\                                                5               350    238   19    196    3
                                                                                                                             RUNX1, SF3B1                                                                                               

  AML\#2       63/♂      sAML            46,XY\[25\]                                                                         JAK2, KMT2A-PTD (MLL-PTD),\                                      8               564    28    \-    \-     \-
                                                                                                                             NRAS, SRSF2, TET2 (VAR)                                                                                    

  AML\#3       76/♂      sAML            46,XY\[17\]                                                                         BCOR, DNMT3A, KMT2A-PTD (MLL-PTD), NRAS, TET2, U2AF1             5               593    119   18    100    4

  AML\#4       63/♀      *de novo* AML   46,XX,t(7;9)(q22;q34),add(17)(p12)\[22\]/46,XX\[3\]                                 ASXL1, DNMT3A, PTPN11, RUNX1                                     65              2407   172   93    137    84

  AML\#5       78/♂      sAML            47,XY,+8\[3\]/46,XY\[17\]                                                           ASXL1, IDH2, SRSF2                                               31              1148   135   73    96     17

  AML\#6       83/♂      *de novo* AML   46,XY\[20\]                                                                         \-                                                               30              793    268   223   293    28

  AML\#7       72/♂      sAML            46,XY\[20\]                                                                         ASXL1, IDH2, SF3B1                                               44              1867   416   389   347    32

  AML\#8       70/♀      *de novo* AML   46,XX\[20\]                                                                         FLT3-ITD, NPM1, TET2                                             16              1122   91    92    64     15

  AML\#9       53/♀      *de novo* AML   46,XX\[25\]                                                                         DNMT3A, FLT3-TKD,\                                               33              5781   348   763   642    85
                                                                                                                             IDH1, NPM1, NRAS                                                                                           

  AML\#10      33/♀      *de novo* AML   46,XX\[20\]                                                                         DNMT3A (VAR), FLT3-ITD,\                                         38              3511   100   46    59     17
                                                                                                                             KMT2A-PTD (MLL-PTD), KRAS                                                                                  

  AML\#11      66/♂      *de novo* AML   47,XY,+8\[13\]/46,XY\[7\]                                                           ASXL1, DNMT3A, IDH2, RUNX1, SRSF2                                34              2893   51    34    35     25

  AML\#12      68/♀      *de novo* AML   51,XX,+1,der(2)t(2;12),der(5) t(5;13),+8, +11,der(12),-der(13),+15,+19,+mar\[25\]   TP53                                                             505             808    215   \-    231    \-

  AML\#13      89/♂      sAML            47,XY,+8\[23\]/46,XY\[2\]                                                           \-                                                               34              2131   205   294   318    119

  AML\#14      47/♂      *de novo* AML   42-46,XY,t(1;4)(p33;q35),del(3q),add(6q),-13,\                                      DNMT3A, TP53                                                     55              \-     \-    \-    \-     \-
                                         -15,-16,-17,-18,+19,+2-4mar \[cp15\]                                                                                                                                                           

  AML\#15      63/♂      *de novo* AML   46,XY\[11\]                                                                         IDH2, NPM1, SRSF2                                                32              \-     756   306   3077   40

  AML\#16      69/♂      sAML            47,XY,+21\[6\]/46,XY\[14\]                                                          DNMT3A, KMT2A-PTD (MLL-PTD), RUNX1                               19              1443   172   88    136    21

  AML\#17      69/♂      sAML            46,XY\[26\]                                                                         FLT3-ITD, GATA2, WT1                                             58              2226   248   145   181    32

  AML\#18      59/♀      *de novo* AML   45,XX\[25\]                                                                         BCOR, ETV6 (VAR), EZH2 (VAR), FLT3-ITD, NPM1, KRAS, TET2 (VAR)   29              1626   \-    \-    \-     \-
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

cancers-11-01493-t002_Table 2

###### 

Cytotoxic efficacy of talazoparib and APE1 inhibitor III in myelodysplastic syndromes/chronic myelomonocytic leukemias and acute myeloid leukemias in relation to chromosomal aberrations. AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; MDS: myelodysplastic syndrome.

            Talazoparib         APE1 inhibitor III   normal karyotype   -Y   -13   -15   -16   -17   -18   Trisomy 1   Monosomy 7   Trisomy 8   Trisomy 11   Trisomy 15   Trisomy 19   Trisomy 21   t(1;4)   t(2;2)   t(2;12)   t(5:13)   t(7;9)   t(9;20)   del(1)(p34p36)   del(3q)   del17p
  --------- ------------------- -------------------- ------------------ ---- ----- ----- ----- ----- ----- ----------- ------------ ----------- ------------ ------------ ------------ ------------ -------- -------- --------- --------- -------- --------- ---------------- --------- --------
  AML\#6                        **Responder**                                                                                                                                                                                                                                           
  AML\#12                                                                                                                                                                                                                                                                               
  MDS\#2    **Responder**                                                                                                                                                                                                                                                               
  AML\#1                                                                                                                                                                                                                                                                                
  AML\#2                                                                                                                                                                                                                                                                                
  AML\#3                                                                                                                                                                                                                                                                                
  CMML\#2                       **Non-responder**                                                                                                                                                                                                                                       
  MDS\#1    **Non-responder**                                                                                                                                                                                                                                                           
  MDS\#3                                                                                                                                                                                                                                                                                
  MDS\#4                                                                                                                                                                                                                                                                                
  CMML\#1                                                                                                                                                                                                                                                                               
  CMML\#3                                                                                                                                                                                                                                                                               
  CMML\#4                                                                                                                                                                                                                                                                               
  AML\#4                                                                                                                                                                                                                                                                                
  AML\#5                                                                                                                                                                                                                                                                                
  AML\#7                                                                                                                                                                                                                                                                                
  AML\#8                                                                                                                                                                                                                                                                                
  AML\#9                                                                                                                                                                                                                                                                                
  AML\#10                                                                                                                                                                                                                                                                               
  AML\#11                                                                                                                                                                                                                                                                               
  AML\#13                                                                                                                                                                                                                                                                               
  AML\#14                                                                                                                                                                                                                                                                               
  AML\#15                                                                                                                                                                                                                                                                               
  AML\#16                                                                                                                                                                                                                                                                               
  AML\#17                                                                                                                                                                                                                                                                               
  AML\#18                                                                                                                                                                                                                                                                               

cancers-11-01493-t003_Table 3

###### 

Cytotoxic efficacy of talazoparib and APE1 inhibitor III in myelodysplastic syndromes/chronic myelomonocytic leukemias and acute myeloid leukemias in relation to gene mutations. AML: acute myeloid leukemia; CMML: chronic myelomonocytic leukemia; MDS: myelodysplastic syndrome; VAR: variation.

            Talazoparib         APE1 inhibitor III   ASXL1           ASXL2   BCOR   CBL   CEBPA   DNMT3A   ETV6   EZH2   FLT3-ITD   FLT3-TKD   GATA1   GATA2   IDH1   IDH2   JAK2   KIT   KMT2A-PTD (MLL-PTD)   NPM1   NRAS   KRAS   PTPN11   RUNX1   SF3B1   SRSF2   TET2   TP53   U2AF1   WT1   ZRSR2
  --------- ------------------- -------------------- --------------- ------- ------ ----- ------- -------- ------ ------ ---------- ---------- ------- ------- ------ ------ ------ ----- --------------------- ------ ------ ------ -------- ------- ------- ------- ------ ------ ------- ----- -------
  AML\#6                        **Responder**        not available                                                                                                                                                                                                                                
  AML\#12                                                                                                                                                                                                                                                                                         
  MDS\#2    **Responder**                                                                                                                                                                                                                                                                         
  AML\#1                                                                                                                                                                                                                                                                                          
  AML\#2                                                                                                                                                                                                                                                              VAR                         
  AML\#3                                                                                                                                                                                                                                                                                          
  CMML\#2                       **Non-responder**                                                                 VAR                                                                                                                                                                             
  MDS\#1    **Non-responder**                                                                     VAR             VAR                                                                                                                                                                             
  MDS\#3                                                                                                                                                                                                                                                                                          
  MDS\#4                                                                                                                                                                                                                                                                                          
  CMML\#1                                                                                                                                                                                                                                                                                         
  CMML\#3                                                                                                                                                                                                                                                                                         
  CMML\#4                                                                                                                                                                                                                                                                                         
  AML\#4                                                                                                                                                                                                                                                                                          
  AML\#5                                                                                                                                                                                                                                                                                          
  AML\#7                                                                                                                                                                                                                                                                                          
  AML\#8                                                                                                                                                                                                                                                                                          
  AML\#9                                                                                                                                                                                                                                                                                          
  AML\#10                                                                                         VAR                                                                                                                                                                                             
  AML\#11                                                                                                                                                                                                                                                                                         
  AML\#13                                            not available                                                                                                                                                                                                                                
  AML\#14                                                                                                                                                                                                                                                                                         
  AML\#15                                                                                                                                                                                                                                                                                         
  AML\#16                                                                                                                                                                                                                                                                                         
  AML\#17                                                                                                                                                                                                                                                                                         
  AML\#18                                                                                                  VAR    VAR                                                                                                                                                 VAR                         
